Literature DB >> 22977481

Frequent expression of MAGE1 tumor antigens in bronchial epithelium of smokers without lung cancer.

Manisha Bhutani1, Ashutosh Kumar Pathak, Hongli Tang, You H Fan, Diane D Liu, J Jack Lee, Jonathan Kurie, Rodolfo C Morice, Waun Ki Hong, Li Mao.   

Abstract

Melanoma antigens (MAGE) are frequently expressed in lung cancer and are promising targets of anticancer immunotherapy. Our preliminary data suggested that MAGE may be expressed during early lung carcinogenesis, raising the possibility of targeting MAGE as a lung cancer prevention strategy. The purpose of this study was to investigate MAGE activation patterns in the airways of chronic smokers without lung cancer. MAGE-A1, -A3 and -B2 gene expression was determined in bronchial brush cells from chronic former smokers without lung cancer by reverse transcription-PCR (RT-PCR). The results were correlated with clinical parameters. The 123 subjects had a median age of 57 years, a median of 40 pack-years smoking history, and had quit smoking for at least one year prior to enrollment. Among the subjects, 31 (25%), 38 (31%), and 46 (37%) had detectable MAGE-A1, -A3 and -B2 expression, respectively, in their bronchial brush samples. Expression of MAGE-A1 and -B2 positively correlated with pack-years smoking history (P=0.03 and 0.03, respectively). The frequency of expression did not decrease despite a prolonged smoking cessation period. In conclusion, MAGE-A1, -A3 and -B2 genes are frequently expressed in the bronchial epithelial cells of chronic smokers without lung cancer, suggesting that chronic exposure to cigarette smoke activates these genes even before the malignant transformation of bronchial cells in susceptible individuals. Once activated, the expression persists despite long-term smoking cessation. These data support the targeting of MAGE as a novel lung cancer prevention strategy.

Entities:  

Year:  2010        PMID: 22977481      PMCID: PMC3440643          DOI: 10.3892/etm.2010.176

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  32 in total

1.  Chromosomal instability and tumors promoted by DNA hypomethylation.

Authors:  Amir Eden; François Gaudet; Alpana Waghmare; Rudolf Jaenisch
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Mage-b4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation.

Authors:  C Osterlund; V Töhönen; K O Forslund; K Nordqvist
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

3.  High expression of MAGE-3 protein in squamous-cell lung carcinoma.

Authors:  C Fischer; F Gudat; P Stulz; C Noppen; C Schaefer; P Zajac; M Trutmann; T Kocher; M Zuber; F Harder; M Heberer; G C Spagnoli
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

4.  Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis.

Authors:  Tobias Peikert; Ulrich Specks; Carol Farver; Serpil C Erzurum; Suzy A A Comhair
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

5.  Expression of cancer/testis (CT) antigens in lung cancer.

Authors:  Kouhei Tajima; Yuichi Obata; Hiromi Tamaki; Masahiro Yoshida; Yao-Tseng Chen; Matthew J Scanlan; Lloyd J Old; Hiroyuki Kuwano; Takashi Takahashi; Toshitada Takahashi; Tetsuya Mitsudomi
Journal:  Lung Cancer       Date:  2003-10       Impact factor: 5.705

6.  Changes in DNA methylation patterns in subjects exposed to low-dose benzene.

Authors:  Valentina Bollati; Andrea Baccarelli; Lifang Hou; Matteo Bonzini; Silvia Fustinoni; Domenico Cavallo; Hyang-Min Byun; Jiayi Jiang; Barbara Marinelli; Angela C Pesatori; Pier A Bertazzi; Allen S Yang
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

7.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2).

Authors:  Victoria Valinluck; Hsin-Hao Tsai; Daniel K Rogstad; Artur Burdzy; Adrian Bird; Lawrence C Sowers
Journal:  Nucleic Acids Res       Date:  2004-08-09       Impact factor: 16.971

8.  Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

Authors:  B Thurner; I Haendle; C Röder; D Dieckmann; P Keikavoussi; H Jonuleit; A Bender; C Maczek; D Schreiner; P von den Driesch; E B Bröcker; R M Steinman; A Enk; E Kämpgen; G Schuler
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

9.  A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.

Authors:  Michael A Morse; Jennifer Garst; Takuya Osada; Shubi Khan; Amy Hobeika; Timothy M Clay; Nancy Valente; Revati Shreeniwas; Mary Ann Sutton; Alain Delcayre; Di-Hwei Hsu; Jean-Bernard Le Pecq; H Kim Lyerly
Journal:  J Transl Med       Date:  2005-02-21       Impact factor: 5.531

10.  A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma.

Authors:  B Van den Eynde; O Peeters; O De Backer; B Gaugler; S Lucas; T Boon
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more
  1 in total

1.  Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer.

Authors:  Xinfeng Chen; Liping Wang; Jinyan Liu; Lan Huang; Li Yang; Qun Gao; Xiaojuan Shi; Jieyao Li; Feng Li; Zhen Zhang; Song Zhao; Bin Zhang; Pierre Van der Bruggen; Yi Zhang
Journal:  Oncol Lett       Date:  2017-02-01       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.